Actively Recruiting
68Ga-AAZTA-NI-093 PET/CT: First-in-human Study
Led by First Affiliated Hospital of Fujian Medical University · Updated on 2024-09-25
10
Participants Needed
1
Research Sites
69 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
68Ga-AAZTA-093 is a novel radiotracer incorporating a hypoxia sensitive nitroimidazole(NI)-moiety and a PSMA-targeting. In this study, we observed the safety, biodistribution, radiation dosimetry and diagnostic value of 68Ga-AAZTA-NI-093 PET/CT in patients with prostate cancer.
CONDITIONS
Official Title
68Ga-AAZTA-NI-093 PET/CT: First-in-human Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Confirmed treated or untreated prostate cancer patients
- Signed written consent
You will not qualify if you...
- Known allergy against PSMA
- Any medical condition that may significantly interfere with study compliance according to the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian, China, 350005
Actively Recruiting
Research Team
W
Weibing Miao, MD
CONTACT
G
Guochang Wang, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here